BPI 43487
Alternative Names: BPI-43487Latest Information Update: 14 Jun 2024
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 14 Jun 2024 Discontinued - Phase-I for Solid tumours in China (PO) (Betta Pharmaceuticals pipeline, June 2024)
- 07 Jan 2022 Phase-I clinical trials in Solid tumours in China (PO) (Betta Pharmaceutical pipeline,
- 14 Jan 2020 NMPA accepts IND application for BPI 43487 (9348553)